Teva Acquires NuPathe for $3.65/Share in Cash, Plus Up to $3.15/Share Based on Zecuity Sales

Teva Pharmaceutical Industries

today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc.

for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, ZECUITY, are achieved over time.